PROCEPT BioRobotics Corporation (PRCT) Income Statement Analysis

See more : PT Sillo Maritime Perdana Tbk (SHIP.JK) Income Statement Analysis – Financial Results

Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

PROCEPT BioRobotics Corporation (PRCT)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.procept-biorobotics.com

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Metric	2023	2022	2021	2020	2019
Revenue	136.19M	75.01M	34.47M	7.72M	6.17M
Cost of Revenue	65.14M	37.93M	18.61M	8.97M	8.05M
Gross Profit	71.05M	37.09M	15.87M	-1.26M	-1.89M
Gross Profit Ratio	52.17%	49.44%	46.02%	-16.26%	-30.56%
Research & Development	48.45M	28.98M	18.99M	16.28M	13.15M
General & Administrative	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00
SG&A	131.77M	88.83M	51.04M	30.27M	28.52M
Other Expenses	0.00	-203.00K	-154.00K	-25.00K	-46.00K
Operating Expenses	180.22M	117.81M	70.03M	46.55M	41.67M
Cost & Expenses	245.36M	155.74M	88.64M	55.52M	49.72M
Interest Income	7.55M	2.01M	121.00K	184.00K	1.15M
Interest Expense	4.00M	5.18M	5.81M	5.26M	724.00K
Depreciation & Amortization	3.81M	4.32M	2.98M	2.70M	1.49M
EBITDA	-98.10M	-77.65M	-51.06M	-45.06M	-39.76M
EBITDA Ratio	-72.03%	-104.93%	-156.77%	-580.32%	-663.85%
Operating Income	-109.17M	-80.72M	-54.16M	-47.80M	-43.55M
Operating Income Ratio	-80.16%	-107.61%	-157.12%	-619.44%	-705.95%
Total Other Income/Expenses	3.27M	-6.43M	-5.69M	-5.22M	1.58M
Income Before Tax	-105.90M	-87.15M	-59.85M	-53.02M	-41.98M
Income Before Tax Ratio	-77.76%	-116.18%	-173.62%	-687.04%	-680.42%
Income Tax Expense	0.00	6.43M	2.53M	5.24M	678.00K
Net Income	-105.90M	-93.58M	-62.38M	-58.26M	-42.65M
Net Income Ratio	-77.76%	-124.76%	-180.96%	-754.89%	-691.41%
EPS	-2.24	-2.11	-1.43	-1.35	-0.99
EPS Diluted	-2.24	-2.11	-1.43	-1.35	-0.99
Weighted Avg Shares Out	47.26M	44.40M	43.68M	43.25M	43.25M
Weighted Avg Shares Out (Dil)	47.26M	44.40M	43.68M	43.25M	43.25M

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

November 1, 2023globenewswire.com

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended...

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

October 25, 2023zacks.com

PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The 7 Best Tech Stocks To Buy Now: October 2023

October 22, 2023investorplace.com

With the innovation sector moving at full speed, it's time for investors to consider the best tech stocks to buy now but not necessarily for the reason you might assume. Yes, the exchange-traded fund Technology Select Sector SPDR Fund (NYSEARCA:...

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

October 16, 2023globenewswire.com

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the...

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

August 22, 2023globenewswire.com

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan. The procedures were...

PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

August 17, 2023globenewswire.com

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...

Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy

August 10, 2023seekingalpha.com

PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, and growth from its installed base, with a record number of systems placed in Q2. Net-net, reiterate buy,...

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

August 1, 2023globenewswire.com

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an upsized underwritten public...